CL2025001171A1 - Compuestos que median la degradacion de proteinas y metodos de uso de los mismos - Google Patents

Compuestos que median la degradacion de proteinas y metodos de uso de los mismos

Info

Publication number
CL2025001171A1
CL2025001171A1 CL2025001171A CL2025001171A CL2025001171A1 CL 2025001171 A1 CL2025001171 A1 CL 2025001171A1 CL 2025001171 A CL2025001171 A CL 2025001171A CL 2025001171 A CL2025001171 A CL 2025001171A CL 2025001171 A1 CL2025001171 A1 CL 2025001171A1
Authority
CL
Chile
Prior art keywords
compounds
methods
protein degradation
mediate protein
mediate
Prior art date
Application number
CL2025001171A
Other languages
English (en)
Inventor
Ritzén Andreas
Ryckmans Thomas
Ann Mcallister Laura
OLEINIKOVAS Vladimiras
Ranieri Beatrice
Fasching Bernhard
LIARDO Elisa
Original Assignee
Monte Rosa Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monte Rosa Therapeutics Ag filed Critical Monte Rosa Therapeutics Ag
Publication of CL2025001171A1 publication Critical patent/CL2025001171A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento, en parte, se describen compuestos que median la degradación de la quinasa 2 dependiente de ciclina (CDK2) y, por lo tanto, son útiles en el tratamiento de diversos trastornos, tales como el cáncer
CL2025001171A 2022-10-26 2025-04-17 Compuestos que median la degradacion de proteinas y metodos de uso de los mismos CL2025001171A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263419575P 2022-10-26 2022-10-26

Publications (1)

Publication Number Publication Date
CL2025001171A1 true CL2025001171A1 (es) 2025-08-22

Family

ID=88965015

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001171A CL2025001171A1 (es) 2022-10-26 2025-04-17 Compuestos que median la degradacion de proteinas y metodos de uso de los mismos

Country Status (2)

Country Link
CL (1) CL2025001171A1 (es)
WO (1) WO2024092039A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025090727A1 (en) 2023-10-25 2025-05-01 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2025224262A1 (en) * 2024-04-25 2025-10-30 Monte Rosa Therapeutics Ag Combination therapies comprising a cdk2 degrader and a cdk4/6 inhibitor
WO2025224249A1 (en) * 2024-04-25 2025-10-30 Monte Rosa Therapeutics Ag Compounds that mediate protein degradation and methods of use thereof
WO2025231420A1 (en) * 2024-05-03 2025-11-06 Albert Einstein College Of Medicine Small molecule degraders of soluble epoxide hydrolase
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
TW202606702A (zh) 2024-08-12 2026-02-16 瑞士商諾華公司 Cdk2抑制劑在治療癌症中之用途
WO2026067831A1 (zh) * 2024-09-30 2026-04-02 杭州胶联生物医药科技有限公司 作为grk2降解剂的新型取代杂环类化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947368B1 (en) * 2019-04-04 2025-09-03 Dana-Farber Cancer Institute, Inc. Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
US11744896B2 (en) * 2020-09-28 2023-09-05 Creighton University Compositions, use, and method for CDK2-PROTACs for cancer therapy and hearing loss
IL303661A (en) * 2020-12-22 2023-08-01 Nikang Therapeutics Inc Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
WO2023069708A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and uses thereof

Also Published As

Publication number Publication date
WO2024092039A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
CO2022001453A2 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CL2022000922A1 (es) Aminas bicíclicas como inhibidores de la cdk2.
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
BR112022011827A2 (pt) Composto, composição farmacêutica, uso de um composto, métodos para tratamento ou profilaxia de câncer e para tratar um paciente com um distúrbio mediado por receptor do fator de crescimento epidérmico, e, invenção
MX2019000199A (es) Sintesis de n-(heteroaril)-pirrolo[3,2-d]pirimidin-2-aminas.
UY38742A (es) Compuestos de 2,3,5-pyrazolo[1,5-a]pirimidina trisustituida
MX2023008327A (es) Anticuerpos inmunomoduladores de anticuerpo-farmaco.
UY38476A (es) Inhibidores de arg1 y/o arg2
CO2023017812A2 (es) Ligandos crbn de (r)-glutarimida y métodos de uso
UY37559A (es) Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
UY40305A (es) Compuestos tricíclicos de triazolo como inhibidores de dgk
CL2024001691A1 (es) Inhibidores de raf quinasa y métodos de uso de los mismos
CO2023010694A2 (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
MX2025001108A (es) Inhibidores de cinasas aminoheteroarílicos.
CO2026005573A2 (es) Compuestos heterobifuncionales y métodos de tratamiento de enfermedades
AR131101A1 (es) Heteroarilfluoroalquenos como inhibidores de dgk
CO2025016192A2 (es) Moléculas y métodos de uso de estas
MX2024005656A (es) Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.
MX2025004864A (es) Compuestos que median la degradacion de proteinas y metodos de uso de los mismos
MX2022016179A (es) Compuestos y metodos para tratar infecciones fungicas.
DOP2025000322A (es) Anticuerpos de nectina-4 y conjugados anticuerpo-fármaco
WO2025181261A9 (en) Cyclopropyl and 1,3,4-oxodiazole compounds that mediate protein degradation and methods of use thereof
CO2026001588A2 (es) Compuestos de fluoroalcoxialquileno-dihidroimidazo[5,1-d]tetrazinona y compuestos relacionados y su uso en el tratamiento de afecciones médicas
MX2025014547A (es) Péptidos grapados y métodos de los mismos